Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

8047 5502

Gwenan White +44 20 8047 5502

Alice Hunt +44 20 8047 5502

European Analyst/

Investor enquiries: David Mawdsley +44 20 8047 5564

Sally Ferguson +44 20 8047 5543

Gary Davies +44 20 8047 5503

US Analyst/Investor enquiries: Frank Murdolo +1 215 751 7002

Tom Curry +1 215 751 5419

References

1. O'Shaughnessy J, et. al. Final presentation for abstract #1015 - A

randomized study of lapatinib (TYKERB(R)) in combination with trastuzumab

vs. lapatinib monotherapy in heavily pretreated HER2-positive metastatic

breast cancer progressing on trastuzumab therapy. To be presented at the

2008 American Society of Clinical Oncology annual meeting.

2. "Glossary." American Cancer Society.

http://www.cancer.org/docroot/gry/gry_0.asp?txtSearch=her2&dictionary

=. Accessed May 7, 2008.

3. Geyer C, et. al. Lapatinib plus capecitabine for HER2-positive advanced

breast cancer. N Engl J Med 2006;355:2733-43.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 /PRNewswire-iReach/ ... a laureate of The Tech Awards 2014, one of ... humanity and spark global change. The Tech Awards, a signature ... Applied Materials, Inc., selected Gradian as one of two laureates ... http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals around ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
... New data presented at annual American Transplant Congress ... R. Carreno, MD, and colleagues in,the Departments of ... -,Lawrence Miller School of Medicine have corroborated the ... in recipients of,kidney transplants using a regular laboratory ...
... 2 Medarex, Inc.,(Nasdaq: MEDX ) ... Phase 1,study of MDX-1106 (ONO-4538: development code ... anti-PD-1 antibody. Data presented from patients with,recurrent ... the safety,tolerability and pharmacokinetic profile of single-dose ...
Cached Medicine Technology:University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
(Date:9/17/2014)... The Oliver Law Group P.C. is urging all ... Non-Sterile Other-Sonic Ultrasound Transmission Gel to contact the Firm ... recourse. Other-Sonic ultrasound gel was recalled by the U.S. ... the product was linked to a 2011 outbreak of ... Oak, Michigan . While victims of this outbreak may ...
(Date:9/17/2014)... September 17, 2014 North Central Surgical ... granted several awards for their top-notch services. The hospital ... orthopedic care and GYN surgery. , Hospital-wide, North Central ... Award™. They have received this award for two years ... top 5 percent in the nation for Patient Safety ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of Discovery ... would be beneficial in this [MDL].” Accordingly, the court ... end of December,” the order further provides, “the court ... , “The plain import of this order is ... to be discussed as these cases progress toward trial,” ...
(Date:9/17/2014)... September 17, 2014 Catalent Pharma ... technologies and development solutions for drugs, biologics and ... OptiPact™, an integrated service and technology offer based ... provided from the company’s 450,000 sq. ft. Kansas ... ability to integrate optimal formulation, development, analytical expertise, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
Breaking Medicine News(10 mins):Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:North Central Surgical Center Receives Several Accolades 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3
... to present findings at AMCP Conference in AprilST. ... Prime Therapeutics (Prime) revealed a significant reduction in ... a retrospective drug utilization review (RetroDUR) program paired ... research was recently published in the American Journal ...
... healing time and pain reduction, , , TUESDAY, April 14 ... production of stem cells appears to "jump-start" the bone-healing ... as fast as young people,s, suggest preliminary results released ... University of Rochester Medical Center in New York gave ...
... Expects to qualify for 180 days of sole marketing ... MYL ) today confirmed that the company and its ... Roche Inc. in connection with the filing of an ... and Drug Administration (FDA) for Capecitabine Tablets, 150 mg ...
... Pearl of Wisdom to Help Prevent Cervical Cancer UPPER MARLBORO, Md., ... knows about and benefits from the tools - the Pap test, ... from this disease. That,s the message that the Pearl of Wisdom(TM) ... women to get - and share - in honor of Mother,s ...
... Versus 2008 First Quarter; , EPS was $1.26, Equal to ... Johnson (NYSE: JNJ ) today announced sales of ... of 7.2% as compared to the first quarter of 2008. ... was 6.0%. Domestic sales declined 5.0%, while international sales declined ...
... The American Federation for Medical Research (AFMR) today has ... sectors to take action against the crisis in U.S. ... major U.S. government agencies, corporations and leading academic institutions ... clinical research from advancing in America. This lack of ...
Cached Medicine News:Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 2Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 3Health News:Slow-Healing Bones May Get Boost From Drug 2Health News:Slow-Healing Bones May Get Boost From Drug 3Health News:Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 3Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 2Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 3Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 5Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 6Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 7Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 8Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 9Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 10Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 11Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 12Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 13Health News:The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research 2
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: